KLDO (Kaleido Biosciences) Other Long-Term Liabilities: $4.30 Mil (As of Dec. 2021)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Kaleido Biosciences Other Long-Term Liabilities?

Kaleido Biosciences KLDO -99.00% Other Long-Term Liabilities is $4.30 Mil as of Dec. 2021.

Kaleido Biosciences's other long-term liabilities for the quarter that ended in Dec. 2021 was $4.30 Mil.

Kaleido Biosciences's quarterly other long-term liabilities increased from Jun. 2021 ($4.08 Mil) to Sep. 2021 ($4.21 Mil) and increased from Sep. 2021 ($4.21 Mil) to Dec. 2021 ($4.30 Mil).

Kaleido Biosciences's annual other long-term liabilities increased from Dec. 2019 ($2.66 Mil) to Dec. 2020 ($3.81 Mil) and increased from Dec. 2020 ($3.81 Mil) to Dec. 2021 ($4.30 Mil).

Kaleido Biosciences Other Long-Term Liabilities Related Terms

Kaleido Biosciences Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences Other Long-Term Liabilities Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Other Long-Term Liabilities
Get a 7-Day Free Trial 55.76 155.44 2.66 3.81 4.30

Kaleido Biosciences Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.81 3.95 4.08 4.21 4.30

Kaleido Biosciences Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $4.30 Mil mean?
Kaleido Biosciences (KLDO) has a Other Long-Term Liabilities of $4.30 Mil as of Dec. 2021. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Kaleido Biosciences and its competitors.
Is Kaleido Biosciences' Other Long-Term Liabilities too high?
Kaleido Biosciences' current Other Long-Term Liabilities is $4.30 Mil.
How does Kaleido Biosciences' Other Long-Term Liabilities compare to NPTX and GSTC?
Kaleido Biosciences' Other Long-Term Liabilities of $4.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Kaleido Biosciences and its competitors. Kaleido Biosciences's current Other Long-Term Liabilities is $4.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current Other Long-Term Liabilities of $4.30 Mil. The current Other Long-Term Liabilities is $4.30 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current Other Long-Term Liabilities is $4.30 Mil as of Dec. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.